CA
NZ
UK
AU
IND
US
Agora, Inc. Chief Executive Officer and Director Zhao Bin filed a Form 4 on November 6, 2026, disclosing three open-market purchases of American Depositary Shares between November 4 and November 6, 2026, all made indirectly through YY TZ Limited pursuant to a Rule 10b5-1 …
Orthofix Medical Inc. filed an 8-K with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing its financial results for the third quarter ended September 30, 2026, through a press release furnished as Exhibit 99.1.
RB Global, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing its third-quarter financial results and a quarterly cash dividend declaration.
Evolv Technologies Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing the appointment of Jason Blessing, age 55, to its Board of Directors effective November 6, 2026.
Shabtai Adlersberg, President and CEO of AudioCodes Ltd, filed a Form 4 on November 9, 2026, disclosing two open-market purchases of ordinary shares totaling 15,939 shares on November 5 and November 6, 2026.
Guy Wagner, CSO and President of Wearable Devices Ltd. (NASDAQ:WLDS), filed a Form 4 on November 9, 2026, disclosing the acquisition of 75,000 Restricted Share Units on November 5, 2026.
Leeor Jacob Langer, Chief Technology Officer of Wearable Devices Ltd., filed a Form 4 on November 9, 2026, disclosing the acquisition of 75,000 Restricted Share Units granted on November 5, 2026, at no cost under the company's 2024 Global Equity Incentive Plan.
Orthofix Medical Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter net sales of $207,862 thousand and a return to operating income of $1,545 thousand.
Turn Therapeutics Inc. filed a Form S-3 registration statement with the SEC on November 9, 2026, registering up to 25,362,950 shares of common stock for resale by selling stockholders, while also converting two prior Form S-1 registration statements into a single shelf registration.
Compass Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a net loss of $27.171 million for the third quarter and a nine-month accumulated deficit surpassing $501 million.
Please wait processing your request...